Filing Flows › Profound Medical (PROF) › Q2 2026 › vs Q2 2025
Profound Medical (PROF) Q2 2026 vs Q2 2025 (year over year)
Profound Medical's revenue rose $272K (+12%) from $2.2M in Q2 2025 to $2.5M in Q2 2026. The biggest changes: Capital equipment +$221K (+34%); Recurring - non-capital +$51K (+3%).
Profound Medical, Q2 2026: revenue $2.5M (+12% year over year), operating margin -445.7%, net loss $9.5M, operating cash flow −$11.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Recurring - non-capital | $1.6M | $1.6M | $51K | +3% |
| Capital equipment | $871K | $650K | $221K | +34% |
| Revenue | $2.5M | $2.2M | $272K | +12% |
| Other income, net | $1.6M | −$1.8M | $3.4M | — |
| Net loss | $9.5M | $15.7M | −$6.2M | -39% |
| Costs & expenses | $13.6M | $17.9M | −$4.3M | -24% |
| Operating costs | $13.5M | $16.0M | −$2.5M | -15% |
| Income tax | $55K | $64K | −$9K | -14% |
| Cost of revenue | $536K | $593K | −$57K | -10% |
| Research & development | $5.7M | $6.1M | −$444K | -7% |
| SG&A | $7.4M | $9.3M | −$2.0M | -21% |
| Operating cash sources | $12.3M | $15.3M | −$3.0M | -19% |
| Depreciation & amortization | $135K | $141K | −$6K | -4% |
| Share-based compensation | $874K | $1.5M | −$577K | -40% |
| Cash used in operations | $11.3M | $13.7M | −$2.4M | -18% |
| Net loss absorbed | $9.5M | $15.7M | −$6.2M | -39% |
| Working capital & other | $2.8M | −$359K | $3.2M | — |
Questions
How much did Profound Medical's revenue grow year over year in Q2 2026?
Profound Medical's revenue rose $272K (+12%) from $2.2M in Q2 2025 to $2.5M in Q2 2026.
What drove Profound Medical's revenue change in Q2 2026?
Capital equipment +$221K (+34%); Recurring - non-capital +$51K (+3%).